陳立宗特聘研究員－論文

PUBLICATIONS

Pancreatic adenocarcinoma

Ch’ang HJ, Chen JS, Bai LY, Yang SH, Chiang NJ, Shan YS*, Huang TL*, Chen LT*. Phase III randomized trial comparing adjuvant gemcitabine versus gemcitabine plus chemoradiation in curatively resected pancreatic cancer – A Taiwan Cooperative Oncology Group Study. (in preparation)
Su YY#, Chiang NJ#, Li CP, Yen CJ, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chuang SC, Bai LY, Chiu CF, Peng CM, Chan DC, Chiu SC, Yang YH, Shan YS*, Chen LT*. Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A Real-world multicenter study with NAPOLI-1 nomogram analysis. Front Oncol (in revision, 2021.11) 2020 IF: 6.244
Su YY#, Chiu YF#, Li CP, Yang SH, Lin J, Lin SJ, Chang PY, Chiang NJ, Shan YS*, Ch’ang HJ*, Chen LT*. A phase II randomized trial of induction chemotherapy followed by concurrent chemo-radiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. Br J Cancer 2021 Dec 17. doi: 10.1038/s41416-021-01649-7. Online ahead of print 2020 IF: 7.64
Wang Y, Jhang DF, Chu TS, Tsao CH, Tsai CH, Chuang CC, Ger TR, Chen LT*, Chang WW*, Liao LD*. An adjustable dark-field acoustic-resolution photoacoustic imaging system with fiber bundle-based illumination. Biosensors (Basel). 2021 Aug 3;11(8):262. doi: 10.3390/bios11080262 2020 IF: 5.274
Shan YS#, Chen LT#, Chang YF#, Wu CH, Lee CT, Chiang NJ, Chao YJ, Yen CJ, Tsai HJ, Huang HE, Tsai CR, Weng YL, Yang HC, Liu HC, Chang JS*. No association between alcohol consumption and pancreatic cancer even among individuals genetically susceptible to the carcinogenicity of alcohol. Sci Rep 2021 Jul 15;11(1):14567.doi:10.1038/s41598-021-94111-w 2020 IF:4.379
Wang YL, Jhang DF, Tsai CH, Chiang NJ, Tsao CH, Chuang CC, Chen LT#, Chang WSW*#, Liao LD*#. In vivo assessment of hypoxia levels in pancreatic tumors using a dual-modality ultra-sound/photoacoustic imaging system. Micromachines 2021 Jun; doi/10.3390/ mi12060668 (*Correspondence, #Equal contribution)
Pen SL, Shan YS, Hsiao CF, Liu TW, Chen JS, Ho CL, Chou WC, Hsieh RK, Chen LT, Ch’ang HJ*. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial. Radiother Oncol. 2021 May;158:146-154.
Hsieh MJ, Weng CC*, Lin YC, Wu CC, Chen LT*, Cheng KH*. Inhibition of β-catenin activity abolishes LKB1 loss-driven pancreatic cyst-adenoma in mice. Int J Mol Sci. 2021 Apr 28;22 (9):4649. (*Correspondence)
Chen LT*, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Early dose modification and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): a post hoc analysis of NAPOLI-1. Pancreatology 2021 Jan;21(1):192-199 (*correspondence) 2019 IF, 3.629
Chang TM, Chu PY, Hung WC, Shan YS, Lin HY, Huang KW, Chang JS, Chen LT, Tsai HJ*. c-Myc promotes lymphatic metastasis of pancreatic neuroendocrine tumor through VEGFC upregulation. Cancer Sci. 2021 Jan;112(1):243-253.
Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ*. An updated analysis of the epidemio-logic trends of neuroendocrine tumors in Taiwan. Sci Rep. 2021 Apr 12;11(1):7881.
Chen CY, Liang SH, Su YY, Chiang NJ, Wang HC, Chiu CF, Chen LT*, Bai LY*. Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: a multi-center retrospective study in Taiwan. PLoS One 2020 Dec 29;15(12):e0244487 (*correspondence) 2019 IF, 2.740
Shan YS＃, Chen LT＃, Wu JS＃, Chang YF, Lee CT, Wu CH, Chiang NJ, Huang HE, Yen CJ, Chao YJ, Tsai HJ, Chen CY, Kang JW, Kuo CF, Tsai CR, Weng YL, Yang HC, Liu HC, Chang JS. Validation of genome-wide association study-identified single nucleotide polymorphisms in a case-control study of pancreatic cancer from Taiwan. J Biomed Sci 2020 May 26; 27(1):69 (# co-first authors) [2019 IF, 5.726]
Macarulla Mercadé T*, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial. Pancreas. 2020 Jan;49(1):62-75.
Su YY, Chiang NJ, Tsai HJ, Yen CJ, Shan YS*, Chen LT. The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a Taiwanese cohort. Sci Report 2020 May;10(1):7420
Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, Rau KM, Choi HJ, Oh DY, Belanger B, Chen LT*. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: subgroup analysis of the NAPOLI-1 study. Cancer Sci 2020 Feb;111(2):513-527.
Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS*, Shan YS*, Chen LT*. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma -TCOG T1211 study. Eur J Cancer 2020 Jan;124:123-130.
Wang HC, Lin YL, Hsu CC, Chao YJ, Hou YC, Chiu TJ, Huang PH, Tang MJ*, Chen LT*, Shan YS*. Pancreatic stellate cells activated by mutant KRAS-mediated PAI-1 upregulation foster pancreatic cancer progression via IL-8. Theranostics 2019 Sep 23;9(24):7168-7183 [equal contribution]
Chen LT*, Macarulla T, Blanc JF, Mirakhur B, de Jong FA, Belanger B, Bekaii-Saab T, Siveke JT. Nomogram for predicting survival in patients treated with liposomal irinotecan plus fluorouracil and leucovorin in metastatic pancreatic cancer. Cancers 2019 Jul 28;11(8). pii: E1068. [2018 IF, 6.162]
Hsu MC, Tsai YL, Pan MR, Shan YS, Cheng HC, Cheng TY, Chen LT, Hung WC*. Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer. J Hematol Oncol 2019 Jul 19;12(1):79 [2018 IF: 8.731]
Hung YH, Hsu MC, Chen LT, Hung WC, Pan MR*. Alteration of epigenetic modifiers in pancreatic cancer and its clinical implication. J Clin Med. 2019 Jun 24;8(6). pii: E903. [2018 IF, 5.688]
Kuo TL, Cheng KH, Chen LT, Hung WC*. Deciphering the potential role of Hox genes in pancreatic cancer. Cancers (Basel). 2019 May 27;11(5). pii: E734. [2018 IF, 6.162]
Weng CC, Hsieh MJ, Wu CC, Lin YC, Shan YS, Hung WC, Chen LT, Cheng KH*. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer. Mol Cancer. 2019 May 20;18(1):96. [2018 IF, 10.679]
Kuo TL, Cheng KH, Shan YS, Chen LT, Hung WC*. β-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer. Theranostics 2019 Jan 1;9(2):324-336 [2017 IF: 8.537]
Macarulla Mercadé T*, Chen LT, Li CP, Siveke JT, Cunningham D, Bodoky G, Blanc JF, Lee KH, Dean A, Belanger B, Wang-Gillam A. Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial. Pancreas. 2020 Jan;49(1):62-75.
Hsu MC, M Pan MR, Chu PY, Tsai YL, Tsai CH, Shan YS, Chen LT, Hung WC*. Protein arginine methyltransferase 3 enhances chemoresistance in pancreatic cancer by methylating hnRNPA1 to increase ABCG2 expression. Cancers 2018 Dec 20;11(1):8 [2017 IF: 5.326]
Macarulla T, Blanc JF, Wang-Gillam A, Chen LT, Siveke JT, Mirakhur B, Chen J, de Jong FA. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer – A subgroup analysis of the pivotal NAPOLI-1 trial. J Geriatr Oncol. 2019 Mar 4. [Epub ahead of print]
Wang-Gillam A*, Hubner R, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, Mirakhur B, Chen LT. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer 2019 Feb;108:78-87. [2017 IF: 7.191]
Hubner R, Cubillo A, Blanc JF, Melisi D, Von Hoff DD, Wang-Gillam A, Chen LT, Becker C, Mamlouk K, Belanger B, Yang YJ, de Jong F, Siveke JT. Health-Related Quality of life in patients with metastatic pancreatic cancer treated with liposomal irinotecan and 5-FU/LV following previous gemcitabine-based treatment in the pivotal phase 3 NAPOLI-1 study. Eur J Cancer 2019;106:24-33 [2017 IF: 7.191]
Chen LT*, Siveke JT, Wang-Gillam A, Li CP, Bodoky G, Dean AP, Shan YS, Jameson GS, Macarulla T, Lee KH, Cunningham D, Blanc JF, Chiu CF, Schwartsmann G, Braiteh FS, Mamlouk K, Belanger B, de Jong FA, Hubner RA. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial. Eur J Cancer 2018 Nov 7;105:71-78. [2017 IF: 7.191]
Wang HC, Hung WC, Chen LT, Pan MR*. From friend to enemy: dissecting the functional alteration of immunoregulatory components during pancreatic tumorigenesis. Int J Mol Sci. 2018 Nov 13;19(11). pii: E3584.
Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ*. The incidence and survival of pancreatic cancer by histology, including rare subtypes: a nationwide cancer registry-based study from Taiwan. Cancer Med 2018 Sep 27.
Kao TM, Liu YS, Shan YS, Ch’ang HJ, Chen LT*. Cure of unresectable locally advanced pancreatic cancer after multidisciplainary therapy. J Cancer Res Practice 2018;5:27-31 (case report)
Chang JS, Chiu YF, Yu JC, Chen LT, Ch’ang HJ*. The role of consolidation chemoradio-therapy in locally advanced pancreatic cancer receiving chemotherapy: An updated systematic review and meta-analysis. Cancer Res Treat 2018 Apr;50(2):562-574.
Chen CC, Chen LL, Li CP, Hsu YT, Jiang SS, Fang CS, Chua KV, Huang SX, Shyr YM, Chen LT, Huang TS*. Myeloid-derived macrophage and secreted HSP90-induce pancreatic ductal adenocarcinoma development. Oncoimmunology 2018 Feb 1;7(5): e1424612
Chu PY, Jiang SS, Shan YS, Hung WC, Chen MH, Lin HY, Chen YL, Tsai HJ*, Chen LT. Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. Oncotarget 2017 Oct 9;8(61):103613-103625
Chang TM, Shan YS, Chu PY, Jiang SS, Hung WC, Chen YL, Tu HC, Lin HY, Tsai HJ*, Chen LT. The regulatory role of aberrant Phosphatase and Tensin Homologue and Liver Kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors. Oncotarget 2017 Sep 16;8(58):98068-98083.
Weng CC, Hawse JR, Subramaniam M, Chang VHS, Yu WCY, Hung WC, Chen LT*, Cheng KH*. KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model. Oncogene 2017 Sep 28;36(39):5532-5543.
Ueno M*, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol. 2017 Aug;80(2):307-315.
Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT; Wan Y, Solem CT, Botteman M, Yang YJ, de Jong F, Hubner RA. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs. 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. Br J Cancer. 2017 May 9;116(10):1247-1253
Wang-Gillam A*, Von Hoff DD, Siveke J, Huber R, Belanger B, Pipas JM, Chen LT, on behalf of NAPOLI-1 Study Group. Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: applicability to clinical situations. J Clin Oncol 2017 Feb 20;35(6):689-690. [Epub ahead of print, Correspondence]
Liu CT, Chen MH, Chen JS,Chen LT, Shan YS, Lu CH, Su YL, Ku FC, Chou WC, Chen YY. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan. Asia Pac J Clin Oncol. 2016 Dec;12(4):396-402.
Chen LT*, Wang-Gillam A, Von Hoff DD, Bayever E, Belanger B. Nanoliposomal irinotecan in metastatic pancreatic cancer – Author response to: Discrepancies between pre-specified and reported outcomes in Wang-Gillam et al. (2016). Lancet 2016 May 14;387(10032):1997 (*correspondence author) [Category: Medicine, General (2014 SCI) 2/154, I.F. 45.217]
Pan MR, Hsu MC, Luo CW,Chen LT, Shan YS, Hung WC. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget. 2016 Aug 12. doi: 10.18632/oncotarget.
Chiang NJ, Shan YS,Chen LT*. Development of nanoliposomal irinotecan in the management of metastatic pancreatic cancer. Expert Opin Pharmacother 2016 May 17:1-8. [Epub ahead of print] [Category: Pharmacology (2014), SCI, 60/255, I.F. 3.534]
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD,Chen LT* for the NAPOLI-1 Study Group. Nanoliposomal irinotecan with 5-fluorouracil and leucovorin in metastatic pancreatic cancer after prior gemcitabine-based therapy (NAPOLI-1): a global, randomized, open-label phase 3 trial. Lancet 2016 Feb;387(10018):545-57. (*correspondence author) [Category: Medicine, General (2014 SCI) 2/154, I.F. 45.217]
Chang JS, Tsai CR,Chen LT*, Shan YS*. Investigating the association between periodontal disease and risk of pancreatic cancer. Pancreas. 2016 Jan;45(1):134-41. (*correspondence author) [Category: Gastroenterology&Hepatology (2014), SCI, 31/76, I.F. 2.959]
Pan MR, Hsu MC,Chen LT, Hung WC. G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation Sci Rep. 2015 Dec 21;5:18709. [Category: Multidiscipline Science (2014 SCI) 5/54, I.F. 5.578]
Chang TC, Shiah HS, Yang CH, Cheng AL, Yeh CG, Chang JY*,Chen LT*. Phase I study of liposome encapsulated irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86 (*correspondence author)
Chang JS,Chen LT, Shan YS, Lin SF, Hsiao SY, Tsai CR, Yu SJ, Tsai HJ. Comprehensive analysis of the incidence and survival patterns of lung cancer by histology, including rare subtypes, in the era of molecular medicine and targeted therapy: A nation-wide cancer registry-based study from Taiwan. Medicine (Baltimore). 2015;94(24):e969. [Category: Medicine, General (2014 SCI) 15/154, I.F. 5.723]
Chiang NJ, Wu SN,Chen LT*. The potent activation of Ca(2+)-activated K(+) current by NVP-AUY922 in the human pancreatic duct cell line (PANC-1) possibly independent of heat shock protein 90 inhibition. J Pharmacol Sci. 2015 Apr;127(4):404-13. [Category: Pharmacology (2014), SCI, 109/255, I.F. 2.590]
Tsai HJ, Tsai CR, Lin SF*,Chen LT*, Chang JS*. Second cancers in patients with neuroendocrine tumors. PLOS ONE 2013 Dec 31;8:e86414 [Category: Multidiscipline Science (2012 SCI) 7/56, I.F. 3.730]
Wang WY, Hsu CC, Wang TY, Li CR, Hou YC, Chu JM, Lee CT, Liu MS, Su JJM, Jian KY, Huang SS, Jiang SS, Shan YS, Lin PW, Shen YY, Lee MTL, Chan TS, Chang CC, Chen CH, Chang IS, Lee YL,Chen LT, Tsai KC. A gene expression signature of epithelial tubulo-genesis and a role for ASPM in pancreatic tumor progression. Gastroenterology 2013 Nov;145:1110-20 [Category: Gastroenterology & Hepatology (2012),SCI,1/74,I.F. 12.82]
Tsai HJ, Wu CC, Tsai CR, Lin SF*,Chen LT*, Chang JS*. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide registry-based study. PLOS ONE 2013 8(4):e6248 (*correspondence author) [2012 SCI, Multidiscipline Science 7/56, I.F. 3.730]
Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh G,Chen LT*. A multinational phase 2 study of nanoliposomal irinotecan (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 2013 Aug 20;109:920-5 (*correspondence author)[Category: Oncology(2012),SCI,35/196,I.F. 5.08]
Ch’ang HJ, Lin YL, Wang HP, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Hwang TL,Chen LT* Induction chemotherapy with gemcitabine, oxaliplatin and 5-FU/leucovorin followed by concomitant chemoradiation in patients with locally advanced pancreatic cancer: a Taiwan Cooperative Oncology Group phase II study. Int J Rad Oncol Biol Physics 2011;81:e749-57. (*correspondence author) [2011 SCI Radiology, 12/116, I.F. 4.105]
Tsai CS, Park JW*,Chen LT*. Nanovector-based therapies in advanced pancreatic cancer. J Gastrointest Oncol 2011;2:185-94. (*Correspondence author)
Ch’ang HJ, Huang CL, Wang HP, Hsiah HS, Chang MC, Jan CM, Chen JS, Tien YW, Hwang TL, Lin JT, Cheng AL,Chen LT*. Phase II study of biweekly gemcitabine followed by oxaliplatin & simplified 48-hr infusion 5-FU/leucovorin (GOFL) in advanced pancreatic cancer. Cancer Chemother Pharmacol. 2009;64:1173-9 (*Correspondence author) [SCI, 89/252, I.F.2.759]
Ch’ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Liu TW, Chang JY, Whang-Peng J,Chen LT*.Phase I study of biweekly gemcitabine, oxaliplatin and simplified 48-hr infusion of fluorouracil/leucovorin (GOFL) for advanced pancreatic cancer. J Gastroenterol Hepatol 2006;21: 874-9 (*Correspondence author) [SCI, 23/46, I.F.1.796]
Shiah HS, Cheng AL, Hsu C, Hsu CH, Liu TW, Chang JY, Jan CM, Chao Y, Yu WL, Chung TR, Whang-Peng J,Chen LT*. Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer. J Gastroenterol Hepatol 2006;21:531-6 (*Correspondence author) [SCI, 23/46, I.F.1.796]
Wu CW, Chen SC, Su YC, Chung WL,Chen LT*. Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin. J Gastroenterol Hepatol 2004;19:716-7 (Letter, *Correspondence author) [SCI, 27/47, I.F. 1.53]
Wang JY, Lian ST, Chen YF, Yang YC,Chen LT, Lee KT, Huang TJ, Lin SR. Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients. Cancer Lett. 2002;180:153-8. [SCI, 57/107, I.F. 1.741]
Chao Y, Liu JM, Li AF, Perng CL, Tiu CM, King KL,Chen LT, Lin WC, Lan C, Whang-Peng J. Palliative MEFLEP therapy in advanced pancreatic cancer: excellent response in a patient with Her-2/neu amplification. Pancreas. 2002; 25:e10-4. [SCI, 55/90, I.F. 1.567]

Gastric Adenocarcinoma

Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, H Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N*. Nivolumab plus S-1/capecitabine plus oxaliplatin versus placebo plus S‑1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable advanced or recurrent HER2-negative gastric/gastroesophageal junction cancer: a multi-centre, randomised, double-blind, phase 3 trial (ATTRACTION-4). Lancet Oncol (accepted, 2011.11) 2020 IF: 41.316
Kang YK, Reck M, Nghiem P, Feng Y, Plautz G, Kim HR, Owonikoko T, Boku N, Chen LT, Lei M, Chang H, Lin WH, Roy A, Bello A, Sheng J. Assessment of hyperprogression verusu the nature course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials. J ImmunoTher Cancer (accepted 2021.11)
Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, H Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N*. Nivolumab plus S-1/capecitabine plus oxaliplatin versus placebo plus S‑1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable advanced or recurrent HER2-negative gastric/gastroesophageal junction cancer: a multi-centre, randomised, double-blind, phase 3 trial (ATTRACTION-4). (accepted 2021.11) (accepted 2021.11)
Chen MH, Lu SN, Chen CH, Lin PC, Jiang JK, D’yachkova Y, Lukanowski M, Cheng R, Chen LT*. How may ramucirumab help improve treatment outcome for patients with gastro-intestinal cancers? Cancers 2021 July 15;13(14):3536. doi: 10.3390/cancers13143536. 2020 IF: 6.639
Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK*. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer. 2021 Mar 20. doi: 10.1007/s10120-021-01173-w. Online ahead of print.
AC Roy, J Shapiro, M Burge, C Karapetis, N Pavlakis, E Segelov, I Chau, F Lordick, LT Chen, A Barbour, N Tebutt, T Price. Management of early stage gastro-oesophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy 2020 Apr;20(4):305-324 [2018 IR, 8.676]
Chen LT*, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Kang YK, Boku N. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer 2020 May; 23(3): 510-519
Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Cheol Chung H, Chen JS, Muro K, Ki Kang W, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Tanimoto M, Chen LT, Boku N*. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2020 Jan;23(1):143-153 [2018 IF, 5.554]
Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019 Feb 1;30(2):250-258. [2018 IF, 14.196]
Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Yamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsui A, Fuji H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N*. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer 2019 Mar;22(2):344-354. [2018 IF: 5.554]
Muro K*, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Che LT, Kato K, Li J, Ryu MH, Wan Zamaniah WI, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshiko T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Taberner J, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 2019 Jan 1;30(1):34-43 [2018 IF, 14.196]
Muro K*, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Wan Zamaniah WI, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Che LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshiko T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Taberner J, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol 2019 Jan 1;30(1):19-33. [2018 IF, 14.196]
Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Yamamoto Y, Chin K, Minashi K, Tsuda M, Yamaguchi K, Machida N, Esaki T, Goto M, Komatsu Y, Nakajima TE, Sugimoto N, Yoshida K, Oki E, Nishina T, Tsui A, Fuji H, Kunieda K, Saitoh S, Omuro Y, Azuma M, Iwamoto Y, Taku K, Fushida S, Chen LT, Kang YK, Boku N*. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer 2018 (accepted) [2017 IF: 5.045]
Kang YK, Boku N *, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M,Chen LT#. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471 (# Steering Committee Member as senior author)
Chu NS, Wu IC*,Chen LT, Chin YY. Beau’s lines in nails: An indicator of recent Docetaxel and 5-FU use. Kaohsiung J Med Sci. 2018 Mar;34(3):181-183.
Chen LT, Oh DY, Ryu MH, Yeh KH, Yeo W, Carless R, Cheng R, Kim JS, Orlando M, Kang YK. Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: a systematic review. Cancer Research Treat 2017 Oct;49(4):851-868 [Category: Oncology (2015) SCI 53/213, I.F. 4.288]
Liu TW,Chen LT* S-1 and leucovorin for gastric cancer: How far can it go? (Commentary) Lancet Oncol 2016 Jan;17(1):12-4. [Category: Oncology (2014) SCI 3/211, I.F. 24.690] (*correspondence author)
Chen MH, Lin J, Hsiao CF, Shan YS, Chen YC,Chen LT, Liu TW, Li CP, Chao Y. A phase II study of sequential capecitabine/oxaliplatin followed by docetaxel/capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial. Medicine (Baltimore). 2016 Jan;95(3):e2565. [Category: Medicine, General (2014 SCI) 15/154, I.F. 5.723]
Shen YC, Li CP, Yen CJ, Hsu C, Lin YL, Lin ZZ,Chen LT, Su WC, Chao Y, Yeh KH, Cheng AL. Phase II multicenter study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. Oncology. 2014 Jul;87(2):104-113. [Category: Oncology (2014) SCI, 126/210 I.F. 2.422]
Shen L, Shan YS, Hu HM, Price T, Sirohi B, Yeh KH, Yang YH, Sano T, Yang KH, Zhang XT, Park SR, Fujii M, Kang YK,Chen LT*. Management of gastric cancer: resource-stratified guidelines. Lancet Oncol 2013 Nov;14(12):e535-47. [Category: Oncology (2014) SCI 3/211, I.F. 24.690] (*correspondence author)
Chen CC, Chy CB, Liu KJ, Hung CY, Chang JY, Pan WY, Cheng YH, Lee KD, Chen MF, Kuo CC*,Chen LT*. Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinomas: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochem Pharmacol 2013 Oct 1;86(7):872-87. doi: 10.1016/j.bcp.2013. 07.25. Epub 2013 Aug 8. [Category: Pharmacology (2014), SCI, 23/255, I.F. 5.009]
Hong KJ, Wu DC, Cheng KH,Chen LT, Hung WC. RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation. J Cell Physiol 2014 Feb;229(2):191-201.[Category: Physiology (2014), SCI, 15/83, I.F. 3.839]
Roy A, Cunningham D, Park SR, Kany YK, Chao Y,Chen LT, Rees C, Lim HY, Tabernero J, Kujundzic M, Cardzic MB, Yeh G, de Gramont A. A randomized phase II study of PEP02, irinotecan or docetaxel as a second line therapy in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 2013; 24:1567-73 [Category: Oncology (2012), SCI, 18/196, I.F. 7.384]
Li CP, Chen JS,Chen LT, Yen CJ, Lee KD, Su WP, Lin PC, Lu CH, Tsai HJ, Chao Y. A phase II study of weekly docetaxel and cisplatin plus oral tegafur/uracil and leucovorin as first line chemotherapy in patients with locally advanced or metastatic gastric cancer. Br J Cancer 2010 Oct 26;103(9):1343-8. [SCI, 36/185, I.F.4.831]
Chen JS, Chao Y, Hsieh RK, Cheng AL, Chen PM, Chiou TJ, Chao TY, Yeh KH,Chen LT*, Whang-Peng J*. A multicenter phase II and pharmacokinetic study of S-1 as first line chemotherapy for advanced gastric cancer in Taiwan. Cancer Chemother Pharmacol 2011 Jun;67(6):1281-9. (*correspondence author) [SCI, 96/237, I.F.2.654]
Chen CC*,Chen LT*, Tsou TC, Pan WY, Yeh SC, Tsai FY, Hsieh HP, Chang JY. Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer 2007;97:334-44 [*equal contribution] [SCI, 36/185, I.F.4.831]
Chao Y, Li CP, Chao TY, Su WC, Hsieh RK, Wu MF, Yeh KH,Chen LT*, Cheng AL*. An open, multi-center, phase II clinical trial to evaluate efficacy and safety of paclitaxel, UFT, and leucovorin in patients with advanced gastric cancer. Br J Cancer 2006;95:159-63 (*correspondence author) [SCI, 36/183, I.F.4.831]
Chan CH, Liu TW,Chen LT*, JY Chang, Whang-Peng J. Long-term complete remission of metastatic gastric cancer after weekly docetaxel, 24-hour infusion of high-dose 5-FU/leucovorin and cisplatin. J Gastroenterol Hepatol 2005;20:1470-1 (*Correspondence author, Letter) [SCI, 23/46, I.F.1.796]
Liu JM,Chen LT, Li AF, Wu CW, Lan C, Chung TR, Shiah HS, Lee KD, Liu TW, Whang-Peng J. Prognostic implications of the expression of erbB2, topoisomerase IIa and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy. Jpn J Clin Oncol. 2004;34:727-32 [SCI, 104/120, I.F. 0.799]
Chao Y, Yeh KH, Chang YJ,Chen LT, Chao TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, Hsieh RK, Cheng AL. A Phase II study of oxaliplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004;90: [SCI, 28/120, I.F. 3.89]
Chen LT, Liu TW, Wu CW, Chung TR, Shiah HS, Jan CM, Liu JM, Whang-Peng J, Chang JY. A phase I study of weekly docetaxel, 24-hour infusion of high-dose 5-FU/leucovorin and cisplatin in patients with advanced gastric cancer. Oncology. 2002;63:239-47. [SCI, 28/107, I.F. 3.009]
Lee KD, Liu TW, Wu CW, Tiu CM, Liu JM, Chung TR, Chang JY, Whang-Peng J,Chen LT*. Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin. Ann Oncol. 2002;13:1151-5. (*Correspondence author) [SCI, 27/107, I.F. 3.153]
Liu JM,Chen LT, Chao Y, Li AF, Wu CW, Liu TS, Shiah HS, Chang JY, Chen JD, Wu HW, Lin WC, Lan C, Whang-Peng J. Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. Cancer Chemother Pharmacol. 2002;49:425-8. [SCI, 47/107, I.F. 2.170]
Lee KD, Chung TR, Shaih HS, Yao NS, Whang-Peng J,Chen LT＊. Palliative treatment of intestinal obstruction in advanced gastric cancer using octreotide. J Int Med Taiwan 1999;10:153-158. (Correspondence author)
Yao NS, Wu CW, Tiu CM, Liu JM, Whang-Peng J,Chen LT＊. Percutaneous trans-hepatic duodenal drainage as an alternative approach in afferent loop obstruction with secondary obstructive jaundice in recurrent gastric cancer. Cardiovasc Intervent Radiol. 1998;21:350-3. (Correspondence author)
Hsu CH, Yeh KH,Chen LT, Liu JM, Jan CM, Lin JT, Chen YC, Cheng AL. Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers. An effective and low-toxic regimen for patients with poor general condition. Oncology 1997;54:275-80. [SCI, 28/107, I.F. 3.009]
DS Perng, CM Jan, WM Wang, LT Chen, CS Liu, TJ Huang, CY Chen. Clinico-pathologic study of gastric carcinoma with duodenal invasion. Kaohsiung J Med Sci. 1996;12(8): 461-465. [SCIE]
DS Perng, CM Jan, WM Wang, LT Chen, YC Su, GC Liu, HJ Lin, TJ Huang, CY Chen. Computed tomography, endoscopic ultrasonography & intraoperative assessment in TN staging of gastric carcinoma. J Formos Med Assoc 1996;95: 378 –85 [SCI]
SA Yang, HM Sheu, LT Chen, HS Yu, CY Chen. Malignant acanthosis nigricans with stomach adenocarcinoma and esophageal papilloma: a case report with the research of cytokeratin. Derm Sinica 1990;8:23-29.
TS Lan, CY Chen, CM Jan, WM Wang, LT Chen: Clinical study on Pm and S gastric cancer. Kaohsiung J Med Sci 1988;4:91-98. [SCIE]

Biliary Tract Cancer

Valle JW*, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, Van Cutsem E, Alfonso JA, Chen LT, Obermannova R, Ettrich TJ, Chen JS, Wasan H, Girvan A, Zhang W, Liu J, Tang C, Ebert PJ, Aggarwal A, McNeely S, Moser B, Oliveira J, Carlesi R, Walgren R, Oh DY. Randomized phase 2 study of the addition of ramucirumab or merestinib to standard first line therapy for advanced or metastatic biliary tract cancer. Lancet Oncol 2021 Oct;22(10):1468-1482 2020 IF: 41.316
Chiang NJ, Chen LT, Shan YS, Yeh CN*, Chen MH*. Development of possible next line of systemic therapies for gemcitabine-resistant biliary tract cancers: A perspective from clinical trials. Biomolecules. 2021 Jan 13;11(1):97
Chiang NJ, Chen MH, Yang SH, Hsu C, Yen CJ, Tsou HH, Su YY, Chen JS*, Shan YS*, Chen LT*. Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study. Liver Int 2020 May 28;40(10):2535-43 doi: 10.1111/liv.14538. [2019 IF, 5.175]
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang CH, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DCL, Bogenrieder T, Twelves C and Cheng AL. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer 2020 Apr;122(9):1324-1332
Yoo CH, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osda M, Helwig C, Dussault I, Ikeda M*. Phase 1 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in Asian patients with pre-treated biliary tract cancer. J Immunother Cancer 2020 May;8(1):e000564
Javle M*, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A, Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA,Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A, Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018 Jan 20;36(3):276-282.
Chiang NJ, Shan YS, Chen JS, Hsu C, Tsou HH, Lee KD, Chiu CF, Rau KM, Ho CL, Yu MS, Huang SF,Chen LT*. Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer. Sci Rep 2016 May 3;6:25369. doi: 10.1038/srep25369 [Category: Multidiscipline Science (2014 SCI) 5/54, I.F. 5.578]
Chiang NJ, Shan YS, Hung WC*,Chen LT*. Epigenetic regulation in the carcinogenesis of cholangiocarcinoma. Int J Biochem Cell Biol. 2015;67:110-4. [Category: Biochemistry & Cell Biology (2014 SCI) 76/290, I.F. 4.076]
Park JO, Oh DY, Hsu C, Chen JS,Chen LT, Orlando M, Kim JS, Lim HY. Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review. Cancer Res Treat. 2015 Jul;47(3):343-61.
Chen JS, Hsu C, Chiang NJ, Tsai CS, Tsou HH, Huang SF, Yen CJ, Lee KD, Chiu CF, Rau KM, Ho CL, Yu MS, Shan YS*, Chao Y*,Chen LT*, on behalf of TCOG. Final results of a KRAS mutation status–stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. Ann Oncol 2015;26:943-9. [2014 SCI, Oncology 18/211 I.F. 7.040] (*correspondence author)
Chang JS*, Tsai CR,Chen LT*. Risk factors for cholangiocarcinoma in Taiwan: a population-based case-control study. PLOS ONE 2013;8(7): e69981. [2012 SCI, Multidiscipline Science 7/56, I.F. 3.730] (*correspondence author)
Li CF,Chen LT, Lin CY, Wang YH, Huang HY,Hsing CH, Tsai CJ, Shiue YL. Loss of epithelial membrane protein-2 expression confers an independent prognosticator in gallbladder carcinoma. Genomic Medicine, Biomarkers, and Health Sciences 2013 (in press)
Liang PI, Li CF,Chen LT, Sun DP, Chen TJ, Hsing CH, Hsu HP, Lin CY. BCL6 over-expression is associated with decreased p19ARF expression and confers an independent prognosticator in gallbladder carcinoma. Tumour Biol. 2013 Oct. DOI 10.1007/s13277-013-1195-z [Category: Oncology (2012), SCI, 102/196, I.F. 2.518]
Sun DP, Lin CY, Tian YF,Chen LT, Lin LC, Lee SW, Hsing CH, Lee HH, Shiue YL, Huang HY, Li CF, Liang PI. Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression. Tumor Biol 2013 Oct;34(5):3059-69. doi:10.1007/s13277-013-0872-2. Epub 2013 May 31 [Category: Oncology (2012), SCI, 102/196, I.F. 2.518]
Wu LC,Chen LT, Lin CY, Tian YF, Sheu MJ, Uen YH, Shiue YL, Wang YH, Yang SJ, Wu WR. Li SH, Iwamuro M, Kobayasshi N, Huang HY, Li CF. Alpha-methylacyl CoA racemase (AMACR) overexpression in gallbladder carcinoma confers an independent prognostic indicator. J Clin Pathol 2012;65:309-14 [2011 SCI, Pathology 32/78, I.F. 2.306]
Li CF, Fang FM, Wang JM, Tzeng CC, Tai HC, Wei YC, Li SH, Lee YT, Wang YH, Yu SC, Shiue YL, Chu PY, Wang WL, LT Chen, Huang HY: EGFR nuclear import in gallbladder carcinoma: nuclear phosphorylated EGFR upregulates iNOS expression and confer independent prognostic impact. Ann Surg Oncol 2012;19:443-454 [SCI, Surgery 9/198, I.F. 4.166]

Hepatocellular carcinoma

Kudo M,Chen LT*, Assenat E, Kang YK, Lim HY, Poon RTP, Vogel A, Daniele B, Furuse J, Brechenmacher T, Slader C, Zhu AX. Reactivation of hepatitis B virus in patients with advanced hepatocellular carcinoma receiving everolimus in the EVOLVE-1 phase III trial. (submitted)
Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y*. A Phase II clinical trial on the combination therapy of PHY906 plus capecitabine in hepatocellular carcinoma. Oncologist. 2021 Mar;26(3):e367-e373
Chen LT*, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, Ikeda M, Lim HY, Ho CF, Choo SP, Ren Z, Malhotra H, Ueno M, Ryoo BY, Kiang TC, Tai D, Vogel A, Cervantes A, Lu SN, Yen CJ, Huang YH, Chen SC, Hsu C, Shen YC, Tabernero J, Yen Y, Hsu CH, Yoshino T, Douillard JY. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol 2020 Mar;31(3):334-351
Abou-Alfa G, Qin SK, Ryoko BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzy F, Colombo M, Starker D, Bolondi L, Vaccaro G, Harris W, Chen ZD, Hubner R, Meyer T, Sun WJ, Harding J, Hollywood E, Wan P, Ly M, Bolamaski J, Johnston A, Lin CC, Chao Y, Chen LT. Phase III randomized study of second line ADI-PEG20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol 2018 Jun 1;29(6):1402-1408.
Surveillance group; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2017 Oct 24. [Epub ahead of print]
Hung YH, Huang HL, Chen WC, Yen MC, Cho CY, Weng TY, Wang CY, Chen YL,Chen LT, Lai MD*. Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells. Oncol Rep. 2017 Feb;37(2):969-978.
Zhu AX, Chen D, he W, Kanal M, Voi M,Chen LT, Daniele B, Furuse J, Kang YK, Poon RT, Vogel A, Chiang DY. Integrative biomarker analyses indicate etiological variation in hepatocellular carcinoma. J Hepatol. 2016 Apr 26. pii: S0168-8278(16)30147-7 [Category: Gastroenterology & Hepatology (2014) SCI, 4/76 I.F. 11.336]
Liang PC, Ch’ang HJ, Hsu C,Chen LT, Shih TF, Liu TW. Dynamic contrast enhanced MRI for hepatocellular carcinoma patients receiving radiation with or without concomitant thalidomide. Hepatol Int. 2015 Apr;9(2):258-68. [Category: Gastroenterology & Hepatology (2014) SCI, 61/76 I.F. 1.780]
Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RTP, Blanc JF, Vogel A, Chen CL, Dorval E, Peck-Radosavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud K, Anak O, Sellami DB,Chen LT. Everolimus for advanced hepatocellular carcinoma after failure of sorafenib: results from the randomized, phase 3 EVOLVE-1 study. JAMA 2014 July 2;213(1):57-67.[Category: Medicine, General & Internal (2012) SCI, 3/155 I.F. 29.987] (#global study co-chair, and senior author)
Finn RS, Poon RTP, Yau T, Klumpen HJ,Chen LT, Kang YK, Kim TY, Gomez-Martin C, Rodriguez-Lope C, Kunz T, Paquet T, Brandt U, Sellami D, Bruix J. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. J Hepatol 2013;59(6):1271-7. [Category: Gastroenterology & Hepatology (2012), SCI, 5/74, I.F. 9.858]
Shiah HS, Chen CY, Lin YJ, Su WC, Chang JY, Winkler R, Whang-Peng J, Lin PW, Huang JD*,Chen LT*. Randomized clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharm Ther 2013;37;62-74 (*correspondence author) [2012 SCI Pharmacology, 32/260, I.F. 4.548]
Chen LT*, Chen MF*, Li LA, Lee PH, Jeng LB, Lin DY, Wu CC, Mok KT, Chen CL, Lee WC, Chau GY, Chen YS, Lui WY, Hsiao CF, Whang-Peng J, Chen PJ*. Long-term results of a randomization trial of adjuvant interferon alpha-2b in virus-related hepatocellular carcinoma with curative resection. Ann Surg 2012 Jan;255(1):8-17 (*correspondence author) [2012 SCI Surgery, 1/198, I.F. 6.392]
Ch’ang HJ, Hsu C, Chen CH, Chang YH, Chang JS,Chen LT. Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012;82:817-25 [2011 SCI Radiology, 12/116, I.F. 4.105]
Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Chen HL, Thomson JA, Whang-Peng J, Chen PJ*,Chen LT*. A randomized phase II study of pegylated arginine deiminase in Asian advanced hepatocellular carcinoma patients. Br J Cancer 2010;103:954-60. (*correspondence author) [2011 SCI Oncology, 36/183, I.F.4.831]
Sheen YC, Hsu C,Chen LT, et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010;52:889-94 [SCI Gastroenterology & Hepatology, 4/72, I.F.9.334]
Chen LT, Shiah HS, Chao Y, Chang JY, Cheng LT, Whang-Peng J. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent. J Clin Oncol. 2009;27(36):e271 [SCI, 4/85, I.F.18.970]
Poon D, Anderson BO,Chen LT, Tanaka K, Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, Khin MW, Koo WH. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009;10: 1111-8. [SCI Oncology, 5/185, I.F.17.764]
Li CP, Chao Y,Chen LT, Lee RC, Lee WP, Yuan JN, Yen SH, Lee SD. Fever after transcatheter arterial chemoembolization for hepatocellular carcinoma: incidence and risk factor analysis. Scand J Gastroenterol. 2008;43:992-9 [SCI, 41/72, I.F.1.996]
Chang CW, Wang TE,Chen LT, Chang WH, Leu YS, Fan YK, Chan YJ. Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literature. Med Oncol. 2008;25:264-8 [SCI, 110/132, I.F.1.356]
Shiah HS, Chao Y,Chen LT*, Yao TJ, Huang JD, Chang JY, Chen PJ, Chuang TR, Chin YH, Whang-Peng J, Liu TW*. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2006; 58:654-64 (*correspondence author) [SCI, 65/187, I.F.2.216]
Chen SC, Tsai HJ, Jan CM, Wang YH,Chen LT*. Low-dose of thalidomide can be effective in advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21: 1868-9 (Letter, *Correspondence author) [SCI, 23/46, I.F.1.796]
Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Chen SC,Chuang TR, Chin YH, Whang-Peng J. Alpha-fetoprotein response predicts survival benefits of thalidomide for advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2005;22:217- [SCI, 30/187, I.F.3.981]
Chen CC, JY Chang, Liu KJ, Chan C, Ho CH, Lee SC,Chen LT*. Hepatocellular carcinoma associated with acquired von Willbrand disease and extreme thrombocytosis. Ann Oncol 2005;16:988-9 (Letter,*Correspondence author) [SCI, 25/123, I.F. 4.34]
Hsu C, Chen CN,Chen LT, Wu CY, Hsieh FJ, Cheng AL. Use of power doppler sonography and circulating angiogenic factors to assess the anti-angiogenic effect of thalidomide in hepatocellular carcinoma. Radiology 2005; 235:509-16. [SCI, 3/84, I.F.5.08].
Wang J,Chen LT, Tsang YM, Liu TW, Shih TT. Dynamic contrast-enhanced MRI analysis of perfusion changes in advanced hepatocellular carcinoma treated with an antiangiogenic agent: a preliminary study. Am J Roentgenol 2004;183:713-9 [SCI, 18/83, I.F. 2.47]
Chang JY, Ka WS, Chao TY, Liu TW, Chung TR, Whang-Peng J,Chen LT*. Hepatocellular carcinoma with intra-atrial tumor thrombi – A report of three cases responsive to thalidomide treatment and literature review. Oncology 2004;67:320-6 (*Correspondence author) [SCI, 52/120, I.F. 2.38]
Hsu C, Chen CN,Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65: 242-9. [SCI, 47/114, I.F. 2.33]
LT Chen, CY Chen, CM Jan, WM Wang, TS Lan, MY Hsieh, GC Liu: Gastrointestinal tract involvement in hepatocellular carcinoma: Clinical, radiological and endoscopical study. Endoscopy 1990; 22:118-123. [SCI]
SC Chen, MY Hsieh, ZY Lin, LY Wang, CM chang, CY Chen, HW Liu, WY Chang, LT Chen, WL Chung, CC Wu, DK Wu, JS Hsieh: Sonographic evaluation of portal vein thrombosis in hepatocellular carcinoma and liver metastasis. Kaohsiung J Med Sci 1986; 2:408-13. [SCI]

Gastrointestinal Stromal Tumor and c-kit-related Researches

Shen CH,Hsieh CC, Jiang KY, Lin CY, Chiang NJ, Li TW, Yen CT, Hwang DY, Chen LT*. AUY922 induces retinal toxicity through attenuating TRPM1. J Biomed Sci 2021 Jul 23;28(1):55. doi: 10.1186/s12929-021-00751-5. (*Correspondence) 2020 IF: 8.41
Lin WH, Wu SY, Yeh TK, Chen CT, Song JS, Shiao HY, Kuo CC, Hsu T, Lu CT, Wang PC, Wu TS, Peng YH, Lin HY, Chen CP, Weng YL, Kung FC, Wu MH, Su YC, Huang KW, Chou LH, Hsueh CC, Yen KJ, Kuo PC, Huang CL, Chen LT, Shih C, Tsai HJ, Jiaang WT. Identification of a multitargeted tyrosine kinase inhibitor for the treatment of gastrointestinal stromal tumors and acute myeloid leukemia. J Med Chem. 2019 Dec 26;62(24):11135-11150.
Hsueh YS, Chang HH, Shan YS, Sun S, Fletcher JA, Li CF*, Chen LT*. Nuclear KIT expression in GISTs: identifying a novel KIT-NFKBIB regulatory axis and its druggability by valproic acid. Oncogene 2019 Sep;38(38):6550-6565 (*corresponding authors)
Yen CC*, Chen LT, Li CF, Chen SC, Chua WY, Lin YC, Yen CH, Chen YC, Yang MH, Chao Y, Fletcher JA. Identification of phenothiazine as an ETV1‑targeting agent in gastrointestinal stromal tumors using the Connectivity Map. Int J Oncol. 2019 Aug;55(2):536-546.
Wu TS, Lin WH, Tsai HJ, Hsueh CC, Hsu T, Wang PC, Lin HY, Peng YH, Lu CT, Lee LC, Tu CH, Kung FC, Shiao HY, Yeh TK, Song JS, Chang JY, Su YC, Chen LT, Chen CT, Jiaang WT, Wu SY. Discovery of conformational control inhibitors switching off the activated c-KIT and targeting a broad range of clinically relevant c-KIT mutants. J Med Chem. 2019 Apr 25;62(8):3940-3957.
Tsai HJ*, Jiaang WT, Shih NY, Fletcher JA, Lin MJ, Yang MY, Chen CT, Hsu TJ, Wu CC, Lin HY, Chen LT. BPR1J373, a novel multitargeted kinase inhibitor, effectively suppresses the growth of gastrointestinal stromal tumor. Cancer Sci. 2018 Nov;109(11):3591-3601.
Li CF, Fang FM, Chen YY, Liu TT, Chan TC, Yu SC,Chen LT#, Huang HY*#. Overexpressed fatty acid synthase in gastrointestinal tumors: Targeting a progression-associated metabolic driver enhances the anti tumor effect of imatinib. Clin Cancer Res. 2017 Aug 15;23(16):4908-4918. (*corresponding; #equally supervised the manuscript)
Yeh CN*, Chen MH, Chen YY, Yang CY, Yen CC, Tzen CY,Chen LT, Chen JS. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget. 2017 Jul 4;8(27):44121-44130.
Kuo HK, Ryu MH, Kim KM, Yang HK, Sasaki A, Hirota S, Zheng J, Tzen CY, Yeh CN, Nishida T*, Shen L*,Chen LT*, Kang YK*. Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor. [Category: Oncology (2015) SCI 53/213, I.F. 4.288] (*corresponding authors)
Chen LT#, Chen CT#, Jiaang WT#, Chen TY, Butterfield JH, Shih NY, Hsu JTA, Lin HY, Lin SF, Tsai HJ. BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT driven myeloid leukemia. Mol Cancer Ther 2016 Aug 10. pii: molcanther. 1006.2015. [Epub ahead of print] [Category: Oncology (2015) SCI, 23/197 I.F. 5.33] (#equally contributed to the manuscript)
Su YY, Chiang NJ, Wu CC,Chen LT. Primary gastrointestinal stromal tumor of the liver in an anorectal melanoma survivor: A case report. Oncol Lett. 2015 Oct;10(4):2366-2370.
Li CF, Fang FM, Lan J, Wang JW, Kung HJ,Chen LT, Chen TJ, Wang YH, Tai HC, Yu SC, Huang HY. AMACR amplification in myxofibrosarcomas: a mechanism of over-expression that promotes cell proliferation with therapeutic relevance. Clin Cancer Res 2014 Dec 1;20(23):6141-52 [Category: Oncology (2014) SCI, 12/197 I.F. 8.722]
Li CF,Chen LT, Lan J, Chou FF, Lin CY, Wang SH, Chen YY, Hu TH, Chen TJ, Li SH, Yu SC, Fang FM, Tai HC, Huang HY. AMACR gene amplification and protein overexpression in primary imatinib-naïve gastrointestinal stromal tumors: driving tumor progression through heightened cell proliferation and indicating negative prognosis. Oncotarget. 2014 Nov 30;5(22):11588-603 [Category: Oncology (2014) SCI, 20/211 I.F. 6.359]
Hsueh YS, Chang HH, Yen CC, Chiang NJ, Li CF,Chen LT*. mTOR inhibition enhances NVP-AUY922-induced autophagy-meditated KIT degradation and tumor growth in imatinib-resistant gastrointestinal stromal tumors. OncoTarget 2014 Nov 30;5(22): 11723-36 [Category: Oncology (2014) SCI, 20/211 I.F. 6.359]
Li CF, Fang FM, Kung HJ,Chen LT, Wang JW, Tsai JW, Yu SC, Wang YH, Huang HY. Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance. Oncotarget. 2014 Nov 30;5(22):11428-41 [Category: Oncology (2014) SCI, 20/211 I.F. 6.359]
Chiang NJ,Chen LT*, Tsai CR, Chang JS*. The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998-2008: a Nation-wide cancer registry-based study. BMC Cancer 2014 Feb 18;14:102. (*correspondence author) [Category: Oncology (2014) SCI, 81/197 I.F. 3.362]
Hsueh YS, Yen CC, Shih NY, Chiang NJ, Li CF,Chen LT*. Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors. Autophagy 2013;9:204-217 (*correspondence author) [2012 SCI, Cell Biology 12/184, I.F. 12.042]
Charoenfuprasert S, Yang Huang HY, Wu WR, Wang YH, Wang JW, Fang FM, Tsai JW, Li SH, Hung HC, Yu SC, Lan J, Shiue YL, Hsing CH,Chen LT*, Li CF*. ASS1 as a novel tumor suppressor gene in myxofibrosarcoma: Aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res. 2013;9(11):2861-2872. (*correspondence author) [2012 SCI, Oncology 14/196, I.F. 7.752]
Hsueh YS, Lin CL, Chiang NJ, Yen CC, Li CF, Ko CH*,Chen LT*. Selecting tyrosine kinase inhibitor(s) for gastrointestinal stromal tumor with secondary c-Kit activation-loop domain mutations: results of a cell-based screening and molecular modeling study. . PLOS ONE 2013;8(6):e65762 (*correspondence author)
YY, Lee YC, Chao KC, Chu PY, Lai CR, Hsu KF, Chang KC, Chen YC,Chen LT, Chang JY, Leu SJ, Shih NY. Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancer. Oncogene. 2011;30:3570-84. [SCI, 15/185, I.F. 7.414]
Lim KH, Huang MJ,Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumours. Med Oncol. 2008;25:207-13. [SCI, 110/185, I.F.2.210]
Hsiao HH, Liu YC, Tsai HJ,Chen LT, Lee CP, Chuan CH, Wang JY, Yang SF, Tseng YT, Lin SF. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute. Kaohsiung J Med Sci. 2006 Dec;22(12):599-603 [SCIE]

MALT lymphoma

Tsa HJ#, Dai JJ, Chen LT#, Wu MS, Yeh KH, Lin CW, Wang TE, Wang SP, Yu FJ, Liou JM, Hsiao CF, Cheng TY, Yeh HJ, Ko CW, Chen MJ, Lo GH, Hsu PI, Chang CS, Hwang WS, Chuang SS, Lee HW, Shun CT, Chiu CF, Wang WM, Hsieh CY, Liu TW, Lin JT, Kuo SH#, Cheng AL. A multicenter prospective study of first-line antibiotic therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma and diffuse large B-cell lymphoma with histological evidence of mucosa-associated lymphoid tissue. Hematologica 2020 Jul;105(7):e349-e354 (Letter, #co-first author) [2019 IF, 7.116]
Chang JS, Kuo SH, Chu PY, Shan YS, Tsai CR, Tsai HJ*, Chen LT. The epidemiology of gastric cancers in the era of Helicobacter pylori eradication: a nation-wide cancer registry-based study in Taiwan. Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1694-1703
Kuo SH, Wu MS, Yeh KH, Lin CW, Hsu PN, Chen LT, Cheng AL. Novel insights of lymphoma-genesis of Helicobacter pylori-dependent gastric mucosa-associated lymphoid tissue lymphoma. Cancers (Basel). 2019 Apr 17;11(4). pii: E547. [2018 IF, 6.162, 31/229 Oncology]
Kuo SH, Yeh KH, Wu MS, Lin CW, Wei MF, Liou JM, Wang HP,Chen LT, Cheng AL*. First-line antibiotic therapy in Helicobacter pylori-negative low-grade gastric mucosa-associated lymphoid tissue lymphoma. Sci Rep. 2017 Oct 30;7(1):14333.
Kuo SH,Chen LT, Lin CW, Yeh KH, Shun CT, Tzeng YS, Liou JM, Wu MS, Hsu PN, Cheng AL*.Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. Blood. 2017 Jan 12; 129(2):188-198
Kuo SH, Tsai HJ, Lin CW, Yeh KH, Lee HW, Wei MF, Shun CT, Wu MS, Hsu PN,Chen LT, Cheng AL*. The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21). J Pathol. 2017 Feb;241(3):420-433
Kuo SH, Yeh KH,Chen LT, Lin CW, Hsu PN, Wu MS, Liou JM, Tsai HJ, Tzeng YS, Cheng AL. Helicobacter pylori CagA translocation is closely associated with the expression of CagA-signaling molecules in low-grade gastric mucosa-associated lymphoid tissue lymphoma. Am J Surg Pathol. 2015 Jun;39(6):761-6
Tsai HJ, Shih NY, Kuo SH, Cheng AL, Lin HY, Chen TY, Chang KC, Lin SF, Chang JS,Chen LT*. AUY922 effectively targets against activated B cell subtype of diffuse large B-cell lymphoma and low-grade lymphoma cells harboring genetic alteration-associated nuclear factor-κB activation. Leuk Lymphoma. 2015 Jan 21:1-9.
Kuo SH, Yeh KH,Chen LT, Lin CW, Hsu PN, Hsu C, Wu MS, Tzeng YS, Wang SP, Cheng AL*. Helicobacter pylori–positive pure diffuse large B-cell lymphoma of stomach – a distinct clinicopathologic entity. Blood Cancer J. 2014;4:e220. [Category: Oncology (2014) SCI, 76/211 I.F. 3.467]
Kuo SH, Tsai HJ, Weng WH, Yeh KH,Chen LT*, Cheng AL*. Beware Imposters: MA-1, a novel MALT lymphoma cell line, is misidentified and corresponds to Pfeiffer, a diffuse large B-cell lymphoma cell line — a Reply: Despite similarities in 8-code STR, MA-1 and Pfeiffer are morphologically, immunophenotypically, cytogenetically and biologically diverse. Cancer Chromosome Gene 2014 Feb;53(2):211-3 (*correspondence author) [SCI, 52/156, Genetics & Hereditary I.F. 3.546]
Kuo SH,Chen LT, Lin CW, Wu MS, Hsu PN, Tsai HJ, Chu CY, Tzeng YS, Wang HP, Yeh KH, Cheng AL. Detection of the Helicobacter pylori CagA protein in gastric mucosa-associated lymphoid tissue lymphoma cells: clinical and biological significance. Blood Cancer J. 2013 Jul 12;3:e125 [Category: Oncology (2011), SCI, 159/196, I.F. 1.400]
Liao F, Hsu YC, Kuo SH, Yang YC, Chen JP, Hsu PN, Lin CW,Chen LT, Cheng AL, CSJ Fann, Lin JT, Wu MS. Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma. Blood Cancer J. 2014 Oct 10;4:eXX
Kuo SH, Cheng AL Yeh KH, Weng WH,Chen LT. No evidence of IGH-MALT1-translocation in the Ma-1 cell line-A reply. Genes Chromosomes Cancer. 2013 Mar 18. doi: 10.1002/gcc.22051. [Epub ahead of print]
SH Kuo, KH Yeh, MS Wu, CW Lin, PN Hsu, HP Wang, LT Chen*, AL Cheng*. H. pylori eradication therapy is effective in the treatment of early-stage H. pylori-positive gastric diffuse large B-cell lymphomas. (*correspondence author) Blood 2012;119:4838-4844 [2011 SCI, Hematology 2/68, I.F. 9.898]
SH Kuo, WH Weng, ZH Chen, PN Hsu, MS Wu, CW Lin, HJ Jeng, KH Yeh, LT Chen*, AL Cheng*. Establishment of a novel MALT lymphoma cell line, MA-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter pylori-independent gastric MALT lymphoma. Cancer Chromosome Gene (*correspondence author) 2011;50:908-21 [SCI, 40/156, I.F. 3.990]
Kuo SH, Hsu CH,Chen LT, Lu YS, Lin CH, Yeh PY, Jeng HJ, Gao M, Yeh KH, Cheng AL. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. Eur J Cancer. 2011;47:1244-57. [SCI, 31/185, I.F. 4.944]
Kuo SH, Cheng AL, Hsu CH, Wu MS, Lin CW, Hsu PN, Yeh KH, Tzeng YS,Chen LT*. t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with gastric mucosa-associated lymphoid tissue lymphoma. Cancer Chemother Pharmacol 2011;68(6):1387-95 (*correspondence author) [SCI, 89/252, I.F.2.759]
Kuo SH, Yen RF, Lin CW,Chen LT, Tien HF, Cheng A. Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma. Ann Hematol. 2010;89:431-6 [SCI, 34/66, 2.688]
Kuo SH, Yeh PY,Chen LT*, Wu MS, Lin CW, Yeh KH, Tzeng YS, Chen JY, Hsu PN, Lin JT, Cheng AL*. Overexpression of B-cell activating factor of TNF family (BAFF) is associated with Helicobacter pylori-independent growth of gastric diffuse large B-cell lymphoma with histologic evidence of MALT lymphoma. Blood 2008;112:2927-34. (*correspondence author) [2010 SCI, 2/66, I.F.10.588]
Kuo SH,Chen LT, Wu MS, Lin CW, Yeh KH, Kuo KT, Yeh PY, Tzeng YS, Wang HP, , Hsu PN, Lin JT, Cheng AL. Long-term follow-up of gastrectomized patients with MALT lymphoma – need for a revisit of surgical treatment. Ann Surg 2008;247:265-269 [SCI, 1/138, I.F.7.747]
Kuo SH,Chen LT, Wu MS, Kuo KT, Yeh KH, Doong SL, Yeh PY, Hsu HC, Tzeng YS, Lin CW, Lin JT, Cheng AL. Differential response to Helicobacter pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach – significance of tumor cell clonality and BCL10 expression. J Pathology 2007;11:296-304 [SCI, 3/76, I.F.7.274]
Cheng TY, Lin JT,Chen LT, Shun CT, Wang HP, Lin MT, Wang TE, Cheng AL, Wu MS. Association of T cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2006;24:3483-9. [SCI, 6/123, I.F.11.810]
Chen LT*, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu PS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J, Cheng AL*. Long-term results of anti-Helicobacter pylori therapy in early-stage high-grade transformed gastric MALT lymphoma. J Natl Cancer Inst 2005;97:1345-53 (*equal contribution) [SCI, 5/123, I.F.13.856]
Yeh KH, Kuo SH,Chen LT*, Mao TL, Doong SL, Wu MS, Hsu HC, Tzeng YS, Chen CL, Lin JT, Cheng AL*. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori–independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005;106:1037-41 (*Correspondence author) [SCI, 3/62, I.F.9.782]
Kuo SH,Chen LT, Chen CL, Doong SL, Yeh KH, Wu MS, Mao TL, Hsu HC, Wang HP, Lin JT, Cheng AL. Expression of CD86 and increased infiltration of NK cells are associated with Helicobacter pylori-dependent state of early stage high-grade gastric MALT lymphoma. World J Gastroenterol 2005;11: 4357-62
Kuo SH*,,Chen LT*, Yeh KH, Wu MS, Hsu HC, Yeh PY, Mao TL, Chen CL, Doong SL, Lin JT, Cheng AL. Nuclear expression of BCL10 or NF-B predicts Helicobacter pylori-independent status of early-stage high-grade gastric mucosa-associated lymphoid tissue lymphomas. J Clin Oncol 2004; 22:3491-7. [*equal contribution] [SCI, 5/120, I.F. 10.86]
Wu MS, Shun CT, Huang SP, Cheng AL,Chen LT, Lin JT. Effect of interleukin-1b and glutathione S-transferase genotypes on the development of gastric mucosa-associated lymphoid tissue lymphoma. Haematologica 2004;89:1015-7. [SCI, 13/62, I.F. 3.45]
Wu MS,Chen LT, Shun CT, Huang SP, Chiu HM, Wang HP, Lin MT, Cheng AL, Lin JT. Promoter polymorphisms of tumor necrosis factor-alpha are associated with risk of gastric mucosa-associated lymphoid tissue lymphoma. Int J Cancer 2004;110:695-700. [SCI, 20/120, I.F. 4.38]
Chen LT, Lin JT, Shyu RY, Jan CM, Chen CL, Chiang IP, Liu SM, Su IJ, Cheng AL. Prospective study of Helicobacter pylori Eradication therapy in stage IE high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001;19: 4245-4251. [SCI, 5/107, I.F. 8.530]
Hsu C, Chen CL,Chen LT, Liu HT, Chen YC, Jan CM, Liu CS, Cheng AL. Comparison of MALT and non-MALT primary large cell lymphoma of the stomach. Cancer. 2001;91:49-56. [SCI, 17/107, I.F. 3.909]
Liu HT, Hsu C, Chen CL, Chiang IP,Chen LT, Chen YC, Cheng AL. Chemotherapy alone versus surgery followed by chemotherapy for stage I/IIE large-cell lymphoma of the stomach. Am J Hematol. 2000;64:175-9. [SCI, 29/59, I.F. 1.535]
Chang CS,Chen LT, Yang JC, Lin JT, Chang KC, Wang JT. Isolation of a Helicobacter pylori protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach. Gastroenterology. 1999;117:82-8. [SCI, 1/47, I.F. 13.020]
CK Chou, LT Chen, RS Sheu, Yang CW, Wang ML, TS Jaw, GC Liu. MRI manifestation of gastrointestinal lymphoma. Abd Imaging 1994;19:495-500

Phase I and Pharmacology

Chang KY*, Chaing NJ, Wu SY, Yen CJ, Chen SH, Yeh YM, Li CF, Feng X, Wu K, Hohnston A, Bomalaski JS, Wu BW, Gao J, Subudhi SK, Kaseb AO, Blando JM, Yadav SS, Szlosarek PW, Chen LT*. Phase Ib study of pegylated arginine deiminase (ADI-PEG 20) plus pembrolizumab in advanced solid cancers. Oncoimmunol 2021 Jul 12;10(1):1943253 (*Correspondence)
Tsai HJ*, Shiah HS, Chang JY, Su WC, Chiang NJ, Chen LT. Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors. Sci Rep. 2021 Mar 1;11(1):4834
Shiah HS, Chiang NJ, Lin CC*, Yen CJ, Tsai HJ, Wu SY, Su WC, Chang KY, Wang CC, Chang JY, Chen LT*. Phase I Dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors. Oncologist 2021 April;26(4): e567-e579. (*Correspondence)
Yoshino T*, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumors with microsatellite instability or NTRK fusions. Ann Oncol. 2020 Apr 6:S0923-7534(20)36386-9.
Leng H, Wang YL, Jhang DF, Chu TS, Tsao CH, Tsai CH, Giamundo S, Chen YY, Liao KW, Chuang CC, Ger TR, Chen LT, Liao LD. Characterization of a fiber bundle-based real-time ultrasound/ photo-acoustic imaging system and in vitro functional imaging application. Micromachines (Basel). 2019 Nov 27;10(12):820.
Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Chen YP, Hsiao HH, Wang MC, Kuo CY, Cortes J,Chen LT*, Chen TY. A phase II study of arginine deiminase, ADI-PEG20 to relapsed/refractory or poor-risk acute myeloid leukemia patients. Sci Rep. 2017 Sep 12;7(1):11253.
Chiang NJ, Chao TY, Hsieh RK, Wang CH, Wang WY, Yeh CG,Chen LT*. A phase I dose-escalation study of PEP-02 in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC Cancer 2016 Nov 21;16(1):907
Chiang NJ, Wu SN, Kao CA, Huang YM,Chen LT*. Stimulation of electroporation-induced inward currents in glioblastoma cell lines by the heat shock protein inhibitor AUY922. Clin Exp Pharmacol Physiol. 2014 Jun 7. doi:10.1111/1440-1681. 12273 [Category: Pharmacology (2014) SCI, 126/254 I.F.2.372] (*correspondence author)
Cheung SE, Lo YC,Chen LT, Kao CA, Wu SN. High effectiveness of triptolide, an active diterpenoid triepoxide, in suppressing Kir-channel currents from human glioma cells. Eur J Pharmacol. 2014 Jun 11. pii: S0014-2999(14)00442-7 [Category: Pharmacology (2012) SCI, 105/261 I.F.2.592]
Wu SN, Lo YC, Chen BS, Cheung So E,Chen LT. Contribution of blocked potassium current conductance and increased conductance of persistent sodium current to the after discharge in myelinated neuron. Muscle Nerve. 2012 Aug;46(2):297-9 [SCI, Neuroscience 150/243, I.F. 2.367]
Delage B, Luong P, Maharaj L, O’Riain C, Syed N, Crook T, Hatzimichael E, Papoudou-Bai A, Mitchell TJ, Whittaker SJ, Cerio R, Gribben J, Lemoine N, Bomalaski J, Li CF, Joel S, Fitzgibbon J,Chen LT, Szlosarek PW. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. Cell Death Dis. 2012 Jul 5;3:e342 [SCI, Cell Biology 35/184, I.F. 6.044]
Lee KD, Pai MY, Hsu CC, Chen CC, Chen YL, Chu PY, Lee CH,Chen LT, Chang JY, Huang TH, Hsiao SH, Leu YW. Targeted Casp8AP2 methylation increases drug resistance in mesenchymal stem cells and cancer cells. Biochem Biophys Res Commun. 2012 May 14. [Epub ahead of print] [SCI, Biochemistry 174/298, I.F. 2.484]
Kuo CC, Liu TW,Chen LT, Shiah HS, Wu CM, Cheng YT, Pan WY, Liu JF, Chen KL, Yang YN, Chen SN, Chang JY. Combination of arsenic trioxide and BCNU synergistically triggers redox-mediated autophagic cell death in human solid tumors. Free Radic Biol Med. 2011;51(12):2195-209 [SCI, 46/286, 5.707, Biochem & Mol Biology]
Yang YN, Chou KM, Pan WY, Chen YW, Tsou TC, Yeh SC, Cheung CH,Chen LT, Chang JY. Enhancement of non-homologous end joining DNA repair capacity confers cancer cells resistance to the novel selenophene compound, D-501036. Cancer Lett. 2011;309:110-8. [SCI, 33/185. I.F. 4.864, Oncology]
Chuang HY, Chang JY, Lai MJ, Kuo CC, Lee HY, Hsieh HP, Chen YJ,Chen LT, Pan WY, Liou JP. 2-amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors. ChemMedChem. 2011;6:450-6 [SCI, 10/54, 3.306, Chemistry, Medicine]
Hsieh CC, Kuo YH, Kuo CC,Chen LT, Cheung CH, Chao TY, Lin CH, Pan WY, Chang CY, Chien SC, Chen TW, Lung CC, Chang JY. Chamacypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells. Biochem Pharmacol. 2010;79:1261-71 [SCI, 19/219, I.F.4.838, Pharmacology]
Wu SN, Chen BS, Wu YH, Peng H,Chen LT. The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. Neurotoxicology. 2009;30:677-85. [SCI, 29/75, I.F.2.409]
Lai MJ, Kuo CC, Yeh TK, Hsieh HP,Chen LT, Pan WY, Hsu KY, Chang JY, Liou JP. Synthesis and structure-activity relationships of 1-benzyl-4,5,6-trimethoxyindoles as a novel class of potent antimitotic agents. ChemMedChem. 2009;4:588-93. [SCI, 8/41, I.F.3.150]
Ma LC, Kuo CC, Liu JF,Chen LT, Chang JY. Transcriptional repression of O6-methylquanine DNA methyltransferase gene rendering cells hyper-sensitive to N,N’-bis(2-chloroethyl)-N-nitrourea in campto-resistant cells. Mol Pharmacol. 2008;74:517-28 [SCI, 29/205, I.F. 4.088]
Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL,Chen LT, Chen CT, Chang JY. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004;64:4621-8. [SCI, 7/120, I.F. 8.649]
Juang SH, Pan WY, Kuo CC, Liou JP, Hung YM,Chen LT, Hsieh HP, Chang JY. A novel bis-benzylidenecyclopentanone derivative, BPR0Y007, inducing a rapid caspase activation involving upregulation of Fas (CD95/APO-1) and wild-type p53 in human oral epidermoid carcinoma cells. Biochem Pharmacol 2004;68:293-303 [SCI,40/185,I.F. 2.99]
Chang JY, Chang CY, Kuo CC,Chen LT, Wei YS, Kuo YH. Salvinal, a novel microtubule inhibitor isolated from salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and –resistant human tumor cells. Mol Pharm 2004;65:77-84. [SCI, 12/185, I.F. 5.65]
Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY,Chen LT, Whang-Peng J; Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37:1320-8. [SCI, 2/45, I.F. 9.825]
Chang JY, Lin CF, Pan WY, Bacherikov V, Chou TC, Chen CH, Dong H, Cheng SY, Tasi TJ, Lin YW, Chen KT,Chen LT, Su TL. New analogues of AHMA as potential antitumor agents: synthesis and biological activity. Bioorg Med Chem. 2003;17:4959-69. [SCI, 22/53, I.F. 2.04]
Chang JY, Hsieh HP, Pan WY, Liou JP, Bey SJ,Chen LT, Liu JF, Song JS. Dual inhibition of topoisomerase I and tubulin polymerization by BPR0Y007, a novel cytotoxic agent. Biochem Pharmacol. 2003;65:2009-2019. [SCI, 24/188, I.F. 3.542]
Chang JY, Liu JF, Juang SH, Liu TW,Chen LT. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res. 2002; 62:3716-21. [SCI, 6/107, I.F. 8.320]
Rastogi K, Chang JY, Pan WY, Chen CH, Chou TC,Chen LT, Su TL. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation. J Med Chem. 2002;45:4485-93 [SCI, 6/36, I.F. 4.139]
Huang TS, Shu CH, Chao Y,Chen LT. Evaluation of GL331 in combination with paclitaxel: GL331’s interference with paclitaxel-induced cell cycle perturbation and apoptosis. Anticancer Drugs. 2001;12:259-66. [SCI, 64/107, I.F. 1.506]
Huang TS, Shu CH, Lee CC,Chen LT, Whang-Peng J. In vitro evaluation of GL331’s cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents. Apoptosis. 2000;5:79-85. [SCI, 125/147, I.F. 0.909]
Huang TS, Lee CC, Chao Y, Shu CH,Chen LT, Chen LL, Chen MH, Yuan CC, Whang-Peng J. A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm Res. 1999;16: 997-1002. [SCI, 32/186, I.F. 2.801]

Colorectal adenocarcinoma

Hung YH, Lai MD, Hung WC, Chen LT*. Semaphorin 4C promotes motility and immune-suppressive activity of cancer cells via CRMP3 and PD-L1. Am J Cancer Res (accepted, 2021.12.22) 2020 IF: 6.166
Yoshino T*, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Chong D,Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2017 Nov 16. [Epub ahead of print]
Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C,Chen LT, de Lima Lopes G Jr, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, Sriuranpong V, Sudoyo AW, Wang JY, Zhang J, Zhang SZ, Ciardiello F, Köhne CH, Shaw M, Kim TW. Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. Clin Colorectal Cancer. 2014 Sep;13(3):145-55.
Lin CY, Tian YF, Wu LC,Chen LT, Lin LC, Hsing CH, Lee SW, Sheu MJ, Lee HH, Wang YH, Shiue YL, Wu WR, Huang HY, Hsu HP, Li CF, Chen SH. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemo-radiation. J Clin Pathol. 2012 May 8. [Epub ahead of print] [SCI, Pathology 32/78, I.F. 2.306]
Hsu TC, Chen HH, Yang MC, Wang HM, Chuang JH, Jao SW, Chaing HC, Wen CY, Tseng JH,Chen LT*. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/ leucovorin as adjuvant therapy for stage III colon cancer in Taiwan. Value Health 2011 Jul-Aug;14:647-51. (*correspondence author) [SCI, 16/72, IF: 2.342, Health Sciences and service]
Chung KP, Chang YJ, Lai MS, Kuo RN, Cheng SH,Chen LT, Tang R, Liu TW, Shieh MJ. Is quality of colorectal cancer care good enough? Core measures development and its application for comparing hospitals in Taiwan. BMC Health Serv Res. 2010;10:27 [SCI, 29/62, I.F.1.680]
Chen LT, Whang-Peng J. Current status of clinical studies for colorectal cancer in Taiwan. Clin Colorectal Cancer 2004;4:196-203. [SCI,
Liu KJ, Wang CC,Chen LT, Cheng AL, Lin DT, Wu YC, Yu WL, Hung YM, Juang SH, Whang-Peng J. Generation of CEA-specific T-cell responses in HLA-A*0201 and HLA-A-*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 2004;10:2645-2651. [SCI, 11/120, I.F. 6.51]
Hsieh RK, Chao TY, Chen WS, Yang TS,Chen LT, Chen PM, Liu JH. Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. Cancer Invest. 2004;22:171-9. [SCI, 63/120, I.F. 2.07]
LT Chen, Huang MS, Wang YL, Liu CS, Jan CM. Utility of argyrophilic nucleolar organizer regions (AgNOR) in differentiating malignant from benign colorectal tumors. Kaohsiung J Med Sci 1995;11:615-620.
LT Chen, CY Chen, CM Jan, DC Wu, MS Huang, WM Wang, YS Pan, TS Chen, DS Perng, YC Su, TJ Huang, HG Wang, HJ Lin. Prognostic significance of tumor cell DNA content on survival in colorectal carcinomas. Chinese J Gastroenterol 1992;9: 111-118.

Tumor Biology

Pan MR, Hsu MC, Chen LT, Hung WC*. Orchestration of H3K27 methylation: mechanisms and therapeutic implication. Cell Mol Life Sci. 2018 Jan;75(2):209-223.
Su CM, Wang MY, Hong CC, Chen HA, Su YH, Wu CH, Huang MT, Chang YW, Jiang SS, Sung SY, Chang JY,Chen LT, Chen PS, Su JL. miR-520h is crucial for DAPK2 regulation and breast cancer progression. Oncogene. 2016 Mar 3;35(9):1134-42.
Chang YW, Tseng CF, Wang MY, Chang WC, Lee CC,Chen LT, Hung MC, Su JL. Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer. Oncogene. 2016 Mar 24;35(12): 1517-28.
Cho CY, Huang JS, Shiah SG, Chung SY, Lay JD, Yang YY, Lai GM, Cheng AL,Chen LT, Chuang SE. Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells. RNA. 2016 Feb;22(2):303-15.
Chen CC, Lee KD, Pai MY, Chu PY, Hsu CC, Chiu CC,Chen LT, Chang JY, Hsiao SH, Leu YW. Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells. Cancer Cell Int. 2015 Oct 13;15:98. [2014 (SCI) 2.77]
Lin MY, Kuo MC, Hung CC, Wu WJ,Chen LT, Yu ML, Hsu CC, Lee CH, Chen HC, Hwang SJ. Association of dialysis with the risks of cancers. PLoS One. 2015 Apr 13;10(4):e0122856.
Lin HP, Lin CY, Huo C, Hsiao PH, Su LC, Jiang SS, Chan TM, Chang CH,Chen LT, Kung HJ, Wang HD, Chuu CP. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1. Oncotarget. 2015 Mar 30;6(9):6684-707.
Lee SW, Chen TJ, Lin LC, Li CF,Chen LT, Hsing CH, Hsu HP, Tsai CJ, Huang HY, Shiue YL. Overexpression of thymidylate synthetase confers an independent prognostic indicator in nasopharyngeal carcinoma. Exp Mol Pathol. 2013 May 28 [Category: Pathology (2011), SCI, 30/78, I.F. 2.425]
Li CF,Chen LT, Lin CY, Huang HY, Hsing CH, Huang CT, Shiue YL. E2F transcription factor 1 overexpression as a poor prognostic factor in patients with nasopharyngeal carcinomas. Genomic Medicine, Biomarkers, and Health Sciences 2013 (in press)
Liang PI, Wang YH, Wu TF, Wu WR, Liao AC, Shen KH, Hsing CH, Shiue YL, Huang HY, Hsu HP,Chen LT, Lin CY, Tai C, Wu JY, Li CF. IGFBP5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. J Clin Pathol. 2013 Mar 28. [Epub ahead of print]. [Category: Pathology (2011), SCI, 32/78, I.F. 2.306]
Kao YC, Lee SW, Lin LC,Chen LT, Hsing CH, Hsu HP, Huang HY, Shiue YL, Chen TJ, Li CF. Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma. Tumor Biol 2012 Dec 4. [Epub ahead of print] [2011 SCI, Oncology 116/196, I.F. 2.143]
Liang PI, Li WM, Wang YH, Wu TF, Wu WR, Liao AC, Shen KH, Wei YC, Hsing CH, Shiue YL, Huang HY, Hsu HP,Chen LT, Lin CY, Tai C, Lin CM, Li CF. HuR cytoplasmic expression is associated with increased cyclin A expression and poor outcome with upper urinary tract urothelial carcinoma. BMC Cancer. 2012 Dec 21;12(1):611. [Category: Oncology (2011), SCI, 78/196, I.F. 3.011]
Liang PI, Wu LC, Sheu JJ, Wu TF, Shen KH, Wang YH, Wu WR, Shiue YL, Huang HY, Hsu HP, Chen YH,Chen LT, Li CF, Liao AC. Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma. J Clin Pathol. 2012;65(9):802-7. [Category: Pathology (2011), SCI, 32/78, I.F. 2.306]

Gastroenterology & Miscellaneous

Huang MY, Hsieh KP, Huang RY, Hung JY, Chen LT, Tsai MJ, Yang YH*. Comparing survival and subsequent treatment of first-line tyrosine kinase inhibitors in patients of advanced lung adenocarcinoma with epidermal growth factor receptor mutation. J Formos Med Assoc. 2021 Mar 9:S0929-6646(21)00076-0
Lin MY, Li WM, Huang CN, Lee HL, Niu SW,Chen LT, Wu WJ, Hwang SJ*. Dialysis increases the risk of bladder recurrence in patients with upper tract urothelial cancer: A population-based study. Ann Surg Oncol. 2018 Apr;25(4):1086-1093.
Sung J, Ng E, Lin JT, Ho KY, Ji JF, Sugano K, Poon R, Chan A, Goh KL, Han KH,Chen LT, Wu KC, Ng S, Bresalier RS, Chan FLK. Digestive cancer management in Asia: Position statements- a report on GI Oncology Summit. J Gastroenterol Hepatol 2012;27:1417-22. [Category: Gastroenterology & Hepatology (2011), SCI, 27/74, I.F. 2.865]
Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Lu YS, Tien HF, Chao TY,Chen LT, Whang-Peng J, Chen PJ. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol 2005;11:5283-8.
Pan YS,Chen LT, Tzeng CA, Su YC, Jang CM, Tsai KB. Clinical and endoscopic features of non-steroind anti-inflammatory drug-induced colorectal ulceration. J Formosa Med Ass 2005;104:804-10. [SCI]
Shiah HS, Liu TW,Chen LT, Chang JY, Liu JM, Chuang TR, Lee WS, Whang-Peng J. Pulmonary embolism after transcatheter arterial chemo-embolization. Eur J Cancer Care 2005;14:440-2. (short report) [SCI, 114/123, I.F.0.638]
Tzeng CA,Chen LT, Tsai KB, Su YC, Wu DC, Jang CM, Wang WM, Pan YS. Acute hemorrhagic rectal ulcer syndrome: a new clinical entity? Report of 19 cases and review of the literature. Dis Colon & Rectum 2004;47:895-903 [SCI, 18/141, I.F. 2.34]
Tzeng CA,Chen LT, Tsai KB, Su YC, Wu DC, Jang CM, Wang WM, Pan YS. Acute hemorrhagic rectal ulcer syndrome: a new clinical entity? Dis Colon & Rectum 2004; 47:904-905 [SCI, 18/141, I.F. 2.34]
Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu CH, Tien HF, Chao TY,Chen LT, Whang-Peng J; Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37:1320-8. [SCI, 2/45, I.F. 9.825]
Cheng KI, Chu KS,Chen LT, Tang CS. Correct positioning of the venous port-a-cath catheter: comparison of intravascular electrocardiography signal from guidewire and sodium bicarbonate flushed catheter. Anaesth Intensive Care. 2002;30:603-7. [SCI, 14/22, I.F. 0.843]
Su YC, Wang WM, Wang SY, Lu SN,Chen LT, Wu DC, Chen CY, Jan CM, Horowitz M. The association between Helicobacter pylori infection and functional dyspepsia in patients with irritable bowel syndrome. Am J Gastroenterol. 2000; 95:1900-5. [SCI, 8/47, I.F. 3.549]
Su YC, Lu SN, Wu DC,Chen LT, Wang WM, Wu DK, Chen CY, Jan CM. Severe gastric mucosa injury after percutaneous pure ethanol injection therapy for hepato-cellular carcinoma. Gastrointest Endosc. 2000;51:350-3. [SCI, 12/47, I.F. 2.776]
Wang WM, Lee SC, Wu DC,Chen LT, Liu CS, Peng CF, Ding HJ, Chen CY, Jan CM. Simplified 13C-urea breath test for the diagnosis of Helicobacter pylori infection–the availability of without fasting and without test meal. Kaohsiung J Med Sci. 2000;16:607-13.
Liu JM, Lin WC, Chen YM, Wu HW, Yao NS,Chen LT, Whang-Peng J. The status of the do-not-resuscitate order in Chinese clinical trial patients in a cancer centre. J Med Ethics. 1999;25:309-14.
Yao NS, Hsu YM, Liu JM,Chen LT, Liau CS. Lung cancer mimicking acute myocardial infarction on electrocardiogram. Am J Emerg Med.1999;17:86-8.
Liu JM, Chen YM, Chao Y, Liu SM, Tiu CM, Wu HW, Chiou TC, Hsieh RK,Chen LT, Whang-Peng J. Continuous infusion cisplatin and etoposide chemotherapy for cancer of unknown primary site (CUPS) in Taiwan, a region with a high prevalence of endemic viral infections. Jpn J Clin Oncol. 1998;28:431-5.
Wang WM, Lee SC, Ding HJ, Jan CM,Chen LT, Wu DC, Liu CS, Peng CF, Chen YW, Huang YF, Chen CY. Quantification of Helicobacter pylori infection: simple and rapid 13C-urea breath test in Taiwan. J Gastroenterol 1998;33:330-5
Hwang WS, Hsiung CA, Ko WS, Wang CC, Chang JY, Lai GM, Hsieh RK, Tsao CJ,Chen LT, Law CK, Cheng AL, Fan SF, Tzeng CH, Chiou TJ, Whang-Peng J. Weekly CAF chemotherapy for advanced breast cancer patients. Oncology 1997;54:293-7. [SCI, 28/107, I.F. 3.009]
Wu DC, Liu JM, Chen YM, Yang S, Liu SM,Chen LT, Whang-Peng J. Mitomycin-C induced hemolytic uremic syndrome: a case report and literature review. Jpn J Clin Oncol. 1997;27:115-8.
Chang CS,Chen LT, Huang SM, Liu TC, Lin SF, Chen TP, Wei TC. Comparison of intravenous granisetron with metoclopramide plus dexamethasone in the prevention of nausea and vomiting associated with emetogenic cytotoxic chemotherapy. Kaohsiung J Med Sci. 1997;13:97-102.
YC Su, WM Wang, LT Chen, W Chiang, CY Chen, SN Lu, CM Jan. High seroprevalence of IgG against Helicobacter pylori among endoscopist in Taiwan. Dig Dis Sci. 1996;41: 1571-6
DS Perng, CM Jan, WM Wang, LT Chen, CS Liu, TJ Huang, CY Chen. Clinico-pathologic study of gastric carcinoma with duodenal invasion. Kaohsiung J Med Sci. 1996;12:461-5
JM Liu, YM Chen, Y Chao, TW Liu, CM Chou, LT Chen, WL Yu, J Whang-Peng. Paclitaxel-induced severe neuropathy in patients with previous radiotherapy to the head and neck region. J Natl Cancer Inst 1996;88:1000-1002 (Letter)
MS Huang, WM Wang, DC Wu, LT Chen, CM Jan, CY Chen, SC Lee. Utility of brushing cytology in the diagnosis of Helicobacter pylori infection. Acta Cytologica 1996;40:714-718.
LT Chen, WM Wang, KB Tsai, CY Chen, CM Jan. Endoscopic resection of esophageal leiomyoma: report of a case. Trans DEST 1995;4(4):365-368.
LT Chen, SA Yang, CS Liu, WM Wang, HS Yu, CY Chen, CM Jan. Multiple esophageal papillomas in malignancy associated acanthosis nigricans: report of a case. Trans DEST 1995;4(4):369-373.
LT Chen, JR Wu, WM Wang, CY Chen, CM Jan. Spontaneous exfoliation of an esophageal leiomyoma after “Drill technique” biopsy: report of a case. Trans DEST 1995;4(3):309-312.
LT Chen, CS Liu, TC Liu, CC Chen, CM Jan, CY Chen. Colonic involvement in Stevens-Johnson syndrome – report of a case. Trans DEST 1995;4(2):23-26.
LT Chen, CS Liu, CM Tang, WM Wang, CM Jan, CY Chen. Autoamputation of polypoid carcinoma – report of a case. Trans DEST 1995;4(2):19-21.
LT Chen, YS Pan, CM Jan, CS Liu, CY Chen. Endoscopic removal of a cavenous lymphangioma of the ascending colon – a case report. Trans DEST 1995;4(1):107-109.
LT Chen, WM Wang, CM Jan, CS Liu, CY Chen. Endoscopic resection of a Brunner’s gland harmatoma of the duodenal bulb – a case report. Trans DEST 1995;4(1):99-102.
CM Tang, LT Chen, CM Jan, WM Wang, YS Huang, JR Wu, CY Chen. Asymptomatic benign carcinoid tumor of the rectum. Trans DEST 1994;3(4):45-57.
LT Chen, CM Jan, WM Wang, YS Huang, JR Wu, CY Chen. Intussusception of the appendix. Trans DEST 1994;3(3):49-51.
YC Su, CM Jan, WM Wang, LT Chen, DC Wu, CS Liu, SB Jong, SH Hu, CY Chen. Does Helicobacter pylori infection play a role in the pathogenesis of non-ulcer dyspepsia – a study of gastric emptying time. Kaohsiung J Med Sci 1995;11: 8-14.
CK Chou, Sheu RS, Yang CW, Wang ML, LT Chen. Abdominal pseudotumors and simulated lymphadenopathy in MRI: differential features with the use of retrograde air insufflation. Abdom Imaging 1994;19: 503-506.
CK Chou, LT Chen, RS Sheu, Yang CW, Wang ML, TS Jaw, GC Liu. MRI manifestation of gastrointestinal lymphoma. Abdom Imaging 1994;19:495-500
WM Wang, CY Chen, CM Jan, LT Chen, DS Perng, SR Lin, CS Liu. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol 1994;89:1793-1796.
CK Chou, LT Chen, RS Sheu, ML Wang, TS Jaw, GC Liu. MRI manifestation of gastrointestinal wall thickening. Abdom Imaging 1994;19:389-394.
CK Chou, GC Liu, JH Su, LT Chen, RS Sheu, TS Jaw. MRI demonstration of peritoneal implants. Abdom Imaging 1994;19:95-101.
YC Su, LT Chen, CM Jan, WM Wang, MY Hsieh, SC Chen, DK Wu, CY Chen. Reappraisal of gastroduodenal lesions after transcatheter arterial chemoembolization of liver neoplasms – selective versus super- selective method. J Clin Gastroenterol 1994;18: 118-121.
WM Wang, CY Chen, CM Jan, LT Chen, DS Perng, SR Lin, CS Liu. Eradication of Helicobacter pylori infection and the recurrence of duodenal ulcers. J Formos Med Assoc. 1993;92:721-724.
CK Chou, GC Liu, LT Chen, TS Jaw. MRI demonstration of peritoneal ligaments and mesenteries. Abdom Imaging 1993;18:126-130.
CK Chou, GC Liu, CW Yang, LT Chen, RS Sheu, TS Jaw. Abdominal MR imaging following antegrade air inflation into the intestinal loops. Abdom Imaging 1993;18: 205-210.
CK Chou, GC Liu, LT Chen, TS Jaw. The use of MRI in bowel obstruction. Abdom Imaging 1993;18:131-135.
CK Chou, GC Liu, LT Chen, TS Jaw. Retrograde air inflation in MRI: a technical note. Abdom Imaging 1993;18:211-214.
CK Chou, GC Liu, LT Chen, TS Jaw. MRI manifestations of peritoneal carcino-matosis. Gastrointest Radiol 1992;17:336-338.
DC Wu, LT Chen, MS Hwang, CM Jan, WM Wang, CS Liu, CY Chen. Flow cytometric analysis of DNA in esophageal cancer. Kaohsiung J Med Sci. 1992; 8:542-551.
DS Perng, CY Chen, CM Jan, WM Wang, LT Chen. Comparison of effect between Omeprazole and Nizatidine in the treatment of duodenal ulcer. J Formosan Med Asso. 1992;91:793-798
WM Wang, CY Chen, CM Jan, TS Lan, LT Chen, SR Lin, CH Chien: Evaluation of urease test, gram stain, culture, and histology in the detection of Campylobacter pylori. J Formosan Med Asso. 1990;89:683-686.
LT Chen, TS Chen, WM Wang, CM Jan, CY Chen: Metastatic testicular choriocarcinoma of the stomach: an unusual cause of massive upper gastrointestinal hemorrhage. Chinese J Gastroenterol 1990:7:197-200.
WM Wang, CY Chen, CM Jan, LT Chen, DC Wu: Central nervous system infection after endoscopic injection sclerotherapy. Am J Gastroenterol 1990; 85:865-867.
LT Chen, CL Chen, WM Wang: The growing teratoma syndrome: a case of primary mediastinal nonseminomatous germ cell tumor treated with chemotherapy and radiotherapy. Chest 1990;98:231-33.
LT Chen, HH Tseng, WS Hwang: Occult prostate adenocarcinoma with pulmonary metastasis: diagnosis by fine needle aspiration biopsy and immunohistochemistry. J Formosa Med Ass 1989;88:940-42.
LT Chen, WS Hwang: Fine needle aspiration of the carotid body paraganglioma. Acta Cytologica 1989;33:681-2.
LT Chen, CY Chen, CM Chang, WM Wang, TS Lan, TS Chen: Incidence of massive re-bleeding from non-bleeding visible vessels in benign gastroduodenal lesions and prospective study in assessing the efficacy of endoscopic hemostasis with local ethanol injection for prevention of re-bleeding. Kaohsiung J Med Sci 1989;5:180-4.
WM Wang, CY Chen, CC Wu, CM Chang, GC Wang, JY Chen, TS Lan, LT Chen, LN SU, SS Her: Clinical evaluation of serum tissue polypeptide antigen in various cancers. J Formosan Med Ass 1988; 5:569-73.

陳立宗 特聘研究員－論文

PUBLICATIONS

陳立宗 特聘研究員級主治醫師

陳立宗特聘研究員－論文

陳立宗特聘研究員級主治醫師